Literature DB >> 25055018

Molecular and genetic pathways in gliomas: the future of personalized therapeutics.

Ryan Grant1, Luis Kolb, Jennifer Moliterno.   

Abstract

In the last few decades, we have seen significant advances in brain imaging, which have resulted in more detailed anatomic and functional localization of gliomas in relation to the eloquent cortex, as well as improvements in microsurgical techniques and enhanced delivery of adjuvant stereotactic radiation. While these advancements have led to a relatively modest improvement in clinical outcomes for patients with malignant gliomas, much more work remains to be done. As with other types of cancer, we are now rapidly moving past the era of histopathology dictating treatment for brain tumors and into the realm of molecular diagnostics and associated targeted therapies, specifically based on the genomic architecture of individual gliomas. In this review, we discuss the current era of molecular glioma characterization and how these profiles will allow for individualized, patient-specific targeted treatments.

Entities:  

Keywords:  1p/19q; Avastin; BRAF inhibitors; EGRF; EGRFvIII; PCV; anaplastic glioma; convection based therapy; cyclin inhibitors; glioblastoma; glioma; glioma vaccines; oligodendroglioma; p53; personalized medicine; temozolamide

Mesh:

Substances:

Year:  2014        PMID: 25055018      PMCID: PMC6128202          DOI: 10.2217/cns.14.7

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  92 in total

Review 1.  The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurosci       Date:  2011-08-03       Impact factor: 34.870

2.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Authors:  J Drappatz; E Q Lee; S Hammond; S A Grimm; A D Norden; R Beroukhim; M Gerard; D Schiff; A S Chi; T T Batchelor; L M Doherty; A S Ciampa; D C Lafrankie; S Ruland; S M Snodgrass; J J Raizer; P Y Wen
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

Review 3.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 4.  Bevacizumab for the treatment of glioblastoma.

Authors:  Sajeel Chowdhary; Marc Chamberlain
Journal:  Expert Rev Neurother       Date:  2013-08-16       Impact factor: 4.618

5.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

Review 6.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

7.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

8.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

9.  Current treatment of low grade gliomas.

Authors:  Martin J van den Bent; Tom J Snijders; Jacoline E C Bromberg
Journal:  Memo       Date:  2012-06-05

10.  Clinical implications of microRNAs in human glioblastoma.

Authors:  Masahiro Mizoguchi; Yanlei Guan; Koji Yoshimoto; Nobuhiro Hata; Toshiyuki Amano; Akira Nakamizo; Tomio Sasaki
Journal:  Front Oncol       Date:  2013-02-07       Impact factor: 6.244

View more
  12 in total

1.  Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR.

Authors:  Xavier Castells; Juan José Acebes; Carles Majós; Susana Boluda; Margarida Julià-Sapé; Ana Paula Candiota; Joaquín Ariño; Anna Barceló; Carles Arús
Journal:  OMICS       Date:  2015-01

2.  BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.

Authors:  Bo Wang; Chen Cao; Xi Liu; Xin He; Hao Zhuang; Dong Wang; Budong Chen
Journal:  Cell Oncol (Dordr)       Date:  2019-11-27       Impact factor: 6.730

Review 3.  Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.

Authors:  Joanna Y Wang; Chetan Bettegowda
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

Review 4.  Genomic discoveries in adult astrocytoma.

Authors:  Joanna Wang; Chetan Bettegowda
Journal:  Curr Opin Genet Dev       Date:  2015-01-20       Impact factor: 5.578

5.  Expression Profile of MiR-128 in the Astrocytoma Patients and Cell Lines.

Authors:  Jingjing Xu; Yuqiong Liu; Si Guo; Shengli Ma; Lin Xiao; Na Wei; Rui Xue
Journal:  Mol Neurobiol       Date:  2015-08-26       Impact factor: 5.590

6.  A pilot study of pre-operative motor dysfunction from gliomas in the region of corticospinal tract: Evaluation with diffusion tensor imaging.

Authors:  Bo Gao; Xudong Shen; Mark S Shiroishi; Mingfan Pang; Zhiqian Li; Benxia Yu; Guiquan Shen
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

7.  Tc-99m Glucoheptonate Single Photon Emission Computed Tomography-Computed Tomography for Detection of Recurrent Glioma: A Prospective Comparison with N-13 Ammonia Positron Emission Tomography-Computed Tomography.

Authors:  Bangkim Chandra Khangembam; Abhinav Singhal; Rajeev Kumar; Chandrasekhar Bal
Journal:  Indian J Nucl Med       Date:  2019 Apr-Jun

8.  A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients.

Authors:  Junmin Xian; Quanzhong Zhang; Xiwen Guo; Xiankun Liang; Xinhua Liu; Yugong Feng
Journal:  FEBS Open Bio       Date:  2019-03-07       Impact factor: 2.693

9.  MiR-4310 induced by SP1 targets PTEN to promote glioma progression.

Authors:  Zhiyong Wu; Jie Luo; Tengyue Huang; Renhui Yi; Shengfeng Ding; Cheng Xie; An'qi Xu; Yu Zeng; Xizhao Wang; Ye Song; Xiaofeng Shi; Hao Long
Journal:  Cancer Cell Int       Date:  2020-12-17       Impact factor: 5.722

10.  From astrocytoma to glioblastoma: a clonal evolution study.

Authors:  Fuhua Yang; Yunding Zou; Qiang Gong; Jieping Chen; Wei-Dong Li; Qilin Huang
Journal:  FEBS Open Bio       Date:  2020-03-22       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.